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ABSTRACT: 
Mass spectrometry performed in non-denaturing conditions (native MS), and its hyphenation to ion 
mobility spectrometry (IM-MS), have gained interest for the qualitative and quantitative 
characterization of intact monoclonal antibody-related (mAb) products. However, one main drawback 
is the manual sample preparation, which hampers its routine use in high throughput automated 
environments. Size exclusion chromatography (SEC) appears as an interesting technique to perform 
online buffer exchange in an automated way. We present here an exhaustive and systematic evaluation 
of the possibilities and versatility of SEC direct hyphenation to native MS or IM-MS (SEC-
nativeMS/IM-MS) for the characterization of a variety of mAb-formats (IgGs, ADCs, bispecific mAbs 
and Fc-fusion proteins). First, online SEC-native MS allows automated sample preparation, resulting in 
high resolution mass spectra and improved mass accuracies (< 80 ppm) compared to manual buffer 
exchange procedures. When hyphenated to ion mobility, SEC-native IM-MS can deliver conformational 
characterization through collision cross section (CCS) measurements within few minutes without 
affecting mAb structures. Finally, benefits of online SEC-nativeIM-MS compared to standalone SEC-
UV or native MS techniques are demonstrated for higher order structure characterization of mAb forced 
degraded samples. While SEC provides separation of high/low molecular weight species from the main 
mAb peak along with precise quantification of the species, native MS affords complementary 
unambiguous identification of SEC peaks, even when poor SEC separation is achieved. The synergic 
online coupling of SEC to native MS/IM-MS is envisioned to definitely push native MS approaches at 
the forefront of mAb characterization in quality-controlled environments and as multiple monitoring 
method. 
HIHGLIGHTS: 
- online SEC-nativeMS for fast and automated sample preparation for mAb analysis 
- SEC-nativeIM-MS for mAb conformational characterization  
- online SEC-nativeMS/IM-MS for characterization of mAb forced degraded samples 
  
1. Introduction 
Monoclonal antibodies (mAbs) and their related compounds make up the largest class in human 
therapeutics to treat various diseases. The success of mAbs stems from their high specificity and affinity, 
long circulating half-lives, ability to induce immune cell effector response, and structural versatility. 
The development of therapeutic mAbs progress considerably, and the Food and Drug Administration 
(FDA) has already approved 75 therapeutic mAbs, including “naked” antibodies, radio-
immunoconjugates, antibody−drug conjugates (ADC), bispecific antibodies (bsAb), Fab fragments and 
Fc-fusion proteins [1].  
Analytical characterization of mAbs and related compounds is pivotal at all stages of compound 
development, from research and development phases, to process control and final batch release [2]. 
Straightforward analytical pipelines, often based on chromatographic, electrophoretic and mass 
spectrometry (MS) methods have been developed to fulfil specific normalized/certified environments 
requirements such as the FDA and the European Medicine Agency (EMA) [3]. Among all the MS-based 
techniques, native MS, and its hyphenation to ion mobility spectrometry (IM-MS) [4], have recently 
been successfully applied for the qualitative and quantitative characterization of intact mAb-related 
products in non-denaturing conditions [5-12]. However, sample preparation is still mostly manual, 
which hampers its routine use in high throughput and automated industrial environments. Indeed, native 
MS analyses have to be performed in a volatile buffer, compatible with electrospray ionization and able 
to maintain weak non-covalent complexes assemblies in solution [13]. Therefore, ammonium acetate 
buffers are classically used for native MS/IM-MS analyses [14]. Sample preparation usually consists of 
manual buffer exchange (also called desalting) into ammonium acetate using a variety of devices 
(microconcentrators, dialysis units, gel filtration devices, etc.), a procedure which is quite time 
consuming, labor intensive and in some cases delicate. This manual buffer exchange step thus appears 
as a major drawback for native MS analysis automation and throughput increase. 
Size exclusion chromatography (SEC) has been suggested for many decades to be coupled to native 
MS/IM-MS, for performing online buffer exchange [15]. Indeed, the SEC separation is based on the 
differences in hydrodynamic volumes and is achieved through a column packed with particles having 
precise pore sizes, which makes SEC interesting for fast buffer exchange. In parallel, SEC with UV 
detection is routinely used in quality control laboratories for the assessment of mAb-product high 
molecular weight species (HMWS) [16] or for determining the content of low molecular species 
(LMWS), such as product fragments. Until recently, the direct coupling of SEC to MS failed, mainly 
because older generation of MS instruments were not sufficiently tolerant to high salt contents (even 
volatile salts like ammonium acetate) and the SEC columns were not enough inert (poor peak shapes 
were generally observed with volatile salts). Most publications report the off-line coupling of SEC to 
either classical denaturing MS (mostly via reversed-phase liquid chromatography coupled to MS, 
RPLC-MS) [17-19] or native MS [20]. In this configuration, SEC fractions are manually collected and 
reinjected into the MS instrument. Direct online coupling of SEC to denaturing MS, using ammonium 
acetate with mobile phase containing organic solvent and/or modifiers for improved chromatographic 
and MS performance, have been reported for proteins [21, 22] and biotherapeutics [22-29] 
characterization. Such experimental conditions affect protein conformation and do not allow 
maintaining protein aggregates. One step further has been reached with the advent of new SEC column 
technologies with reduced particle sizes (< 5 µm) and improved chemical inertness, allowing direct 
hyphenation of SEC to native MS. Recently, Van der Rest et al. have reported the use of online SEC-
native IM-MS, as a valuable technique to desalt samples and provide solution and gas-phase structural 
information in a single stage experiment [30]. The use of online SEC-native MS for site-specific 
antibody drug conjugate (3G-ADC) analysis [9] or mAb aggregates was also recently reported [31]. 
Here, we present an extensive and systematic evaluation of the possibilities to hyphenate SEC to native 
MS or IM-MS (further referred to as SEC-nativeMS/IM-MS) for the characterization of different mAb 
formats. We first evaluated the possibility and efficiency of online SEC-native MS/IM-MS for fast 
desalting and highlighted the versatility of the developed analytical method. Native IM-MS data 
obtained from off-line manual buffer exchange procedures and online SEC-native IM-MS were 
compared. The online SEC-native MS/IM-MS methodology was further used for 22 FDA and EMA 
approved antibody drugs, including IgGs, ADCs, bsAbs and Fc-fusion proteins, highlighting the method 
versatility. Finally, benefits of online SEC-native IM-MS compared to standalones SEC-UV or native 
MS techniques were demonstrated for higher order structure characterization of mAb aggregates and 
size-variants. 
  
2. Materials and methods 
 
2.1. Antibody drugs and chemicals 
Antibodies and related products were obtained as European Union pharmaceutical-grade drug product 
from their respective manufacturers. The NIST mAb reference Material 8671 was purchased from the 
National Institute Standards & Technology (Gaithersburg, MD, USA). All chemicals were purchased 
from Sigma-Aldrich: ammonium acetate (A1542), cesium iodide (21004), 2-propanol (I9516). 
IgGZERO (A0-IZ1–010) enzyme were obtained from Genovis. All the aqueous solutions were prepared 
using an ultra-pure water system (Sartorius, Göttingen, Germany).  
2.2. Deglycosylation 
The deglycosylation was performed by incubating one unit of IgGZERO per microgram of ADC during 
30 min at 37 °C. 
2.3. Manual Buffer exchange 
Prior to native MS, mAbs were desalted against a 150 mM ammonium acetate solution (pH 6.9) using 
6 cycles of concentration/dilution on a microconcentrator (Vivaspin, 50-kD cutoff, Sartorius, Göttingen, 
Germany). Protein concentration was determined by UV absorbance using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific, France). 
2.4. Preparation of forced degraded mAbs 
100 µg of trastuzumab was diluted to 1 mg/mL in 25 mM His, 150 mM NaCl, 6% saccharose (w/v) 
0.005% tween 80 (v/v) buffer at pH 6.5. The mAb was stressed by different pH steps as described Kukrer 
et al [20]. Briefly, the pH stress sequence consists in changing the pH from 6.0 to 1.0, then from 1.0 to 
10.0, from 10.0 to 1.0 and finally to adjust the pH to 6.0. The stressed mAb was concentrated using one 
cycle with microconcentrator (Vivaspin, 10-kD cutoff, Sartorius, Göttingen, Germany). For NISTmAb, 
a 10 mg/mL solution was incubated at 40°C during 8 weeks. 
2.5. Size exclusion chromatography coupled to native MS and IM-MS 
An Acquity UPLC H-class system (Waters, Manchester, UK) comprising a quaternary solvent manager, 
a sample manager set at 10 °C, a column oven and a TUV detector operating at 280 nm and 214 nm 
hyphenated to a Synapt G2 HDMS mass spectrometer (Waters, Manchester, UK) was used for the online 
SEC-native MS/IM-MS instrumentation.  
Several Acquity BEH SEC columns with different nominal pore sizes, lengths and particle sizes were 
evaluated: an Acquity BEH SEC 200Å, 1.7µm, 4.6 x 300 mm, an Acquity BEH SEC 200Å, 1.7µm, 4.6 
x 150 mm, an Acquity BEH SEC 200Å, 1.7µm, 4.6 x 30 mm, an Acquity BEH SEC 125Å, 1.7µm, 4.6 
x 30 mm, all from Waters (Waters, Manchester, UK). For benchmarking of mAb-based compounds, an 
Acquity BEH SEC column (4.6 x 150 mm, 1.7 µm particle size, 200Å pore size) from Waters 
(Manchester, UK) was used with an isocratic elution of 100 mM NH4OAc (pH 6.8) with the following 
flow rate gradient : 0.25 mL/min over 4.1 min; then, 0.10 mL/min over 5.5 min and finally 0.25 mL/min 
over 2.4 min.  
The Synapt G2 HDMS was operated in the positive mode with a capillary voltage of 3.0 kV. The sample 
cone and pressure in the interface region were set to 180 V and 6 mbar, respectively. Acquisitions were 
performed in the m/z range 1000– 8000 for fast desalting experiments and in the m/z range 1000-15000 
for forced degraded samples, both with a 1.5 s scan time. External calibration was performed using 
singly charged ions produced by a 2 g/L solution of cesium iodide in 2-propanol/water (50/50 v/v). MS 
data interpretations were performed using Mass Lynx V4.1 (Waters, Manchester, UK). 
For native IM-MS experiments, the Synapt G2 HDMS instrument was carefully tuned to achieve a good 
compromise between ion separation and IM resolution. Low accelerating voltages were used, especially 
before the IM cell, to guide the ions through the mobility cell to the TOF analyzer without ion activation. 
The backing pressure in the interface region was 6.0 mbar, and the sampling cone was operated at either 
80 V for benchmarking of mAb-based compounds, or180 V for forced degraded samples to find out the 
best compromise between HMWS ion transmission and reduced assemblies dissociation. The argon flow 
rate in the ion trap was 5 mL/min, and the trap collision energy was set to 4 V. Prior to IM separation, 
ions were thermalized in the helium cell (130 mL/min). IM ion separation was performed in the 
pressurized ion mobility cell using a constant N2 flow rate of 45 mL/min. The IM wave height and 
velocity were 40 V and 923 m/s, respectively. Transfer collision energy was fixed to 2 V to extract the 
ions from the IM cell to the TOF analyzer. IM data were calibrated to perform CCS calculations using 
the most intense charge states of 3 external calibrants (i.e., concanavaline A, pyruvate kinase, alcohol 
dehydrogenase for benchmarking and glutamate dehydrogenase, pyruvate kinase, alcohol 
dehydrogenase for forced degraded samples) in non-denaturing conditions as described elsewhere [11, 
12, 32]. IM-MS experiments were performed in triplicate under identical instrumental conditions. 
2.6. Average DAR calculation 
The average DAR value represents the sum of relative peak area for each DAR multiplied by its 
corresponding number of drugs [33]. It was calculated from the relative peak intensities measured either 
from the raw mass spectrum, by using Equation 1. 
𝐷𝐴𝑅𝑎𝑣 =  
∑ 𝑘 ∙ 𝐼𝑘
8
0
∑ 𝐼𝑘
8
0
 (1) 
Where k is the number of drugs and Ik is the relative peak intensity of DARk.  
3. Results and discussion 
 
3.1. SEC as fast desalting method for automated native MS and IM-MS 
A first application of the hyphenation of SEC to native MS focuses on the improvement of sample 
preparation for native MS. Indeed, the implementation of native MS in biopharmaceutical analytical 
workflows is hampered by the relatively low throughput of manual and time-consuming sample 
preparation consisting of buffer exchange. We thus evaluated SEC, with ammonium acetate as mobile 
phase, as an alternative to manual desalting to reach high throughput for native MS/IM-MS analysis. 
3.1.1. Optimization of the SEC-HPLC flow rate  
We first optimized the SEC ammonium acetate flow rate using an Acquity BEH200 4.6x300mm, 1.7µm 
(Waters) with trastuzumab as model mAb to reach the best compromise between high MS signal 
intensity and efficient desalting (estimated from MS peak resolution, defined as RFWHM = M/ΔMFWHM). 
Figure 1 (red trace) shows the SEC-native MS mass spectrum obtained with a constant ammonium 
acetate (100 mM, pH 6.8) flow rate of 0.25 mL/min classically used in LC-MS runs, which reveals a 
relatively low MS intensity of 3.9x102 counts for a 18 min run. The ammonium acetate flow rate was 
next reduced to 0.10 mL/min (Fig. 1, blue trace), inducing a 5-fold increase in MS peak intensities 
(1.8x103 counts), in agreement with better ESI efficiencies at lower flow rates. Of course, the run time 
concomitantly increases with lower flow rates (42 min compared to 18 min), which is not anymore 
compatible with high throughput requirements. To get a compromise between runtime and optimized 
native MS signals, we further optimized an ammonium acetate 3-steps flow rate gradient, in which the 
flow rate was initially set to 0.25 mL/min during 4.1 min and sent to the waste, then it was reduced to 
0.1 mL/min during analyte elution and MS detection, and finally increased to 0.25 mL/min again for 
fast non-volatile salt elution to waste. 
- Figure 1 -  
 
3.1.2. Evaluation of different SEC columns geometries for mAb desalting  
To determine the best SEC column geometry for fast desalting of mAbs, we chose to focus on 
commercial BEH columns (Waters, see Material and methods), available with a variety of pore sizes 
and lengths but having always the same column chemistry. Online SEC-native MS analysis could be 
successfully achieved with any of the tested columns (see Fig. 2), but obviously longer run times were 
obtained with longer columns (i.e. 20 min for the 4.6x300mm vs 4 min for the 4.6x30mm using the same 
particle size). Slight peak tailing was observed with the longest columns (150 mm and 300 mm, Fig. 2C 
and 2D) that could be mainly explained by mAb adsorption on the BEH phase. MS peak resolutions 
were in the same order of magnitude for all the columns (2300 to 2900 at m/z 5294.6, Fig. 2, right panel), 
with the highest resolution values obtained on the longest columns, and mass accuracies always remain 
lower than 40 ppm. This is in agreement with the fact that longer columns provide more efficient 
discrimination of low molecular weight salts and high molecular weight mAbs. As a consequence less 
residual salt adducts were present on the mass spectrum, leading to thinner MS peaks and subsequent 
increased mass accuracies. Broader MS peaks were obtained for the 125Å particle size column, as such 
small pore size was not adapted to 150 kDa mAb molecules eluting in the exclusion volume of the SEC 
column. For high throughput purposes resulting in less than 5 min runs, the shortest columns (30 mm) 
with smaller pore size (125 or 200 Å) should be preferentially selected (see Fig. 2A and 2B). At this 
stage, two conclusions can be drawn: i) long columns with 20 min run times afford best chromatographic 
efficiencies and MS peak resolutions while ii) short columns with small pore sizes resulting in 3-5 min 
runs should be preferred for high throughput applications.  
 
- Figure 2 -  
 3.1.3. Comparison of online SEC-native MS and manual desalting 
We next compared the MS desalting efficiency of SEC compared to manual desalting using 
microconcentrators (see Material and Methods). Figure 3 presents a zoom on the 27+ charge state of 
trastuzumab obtained either after manual desalting (red trace) or after SEC-native MS using two 
different SEC columns of the same porosity but different lengths (blue and green traces). In both cases, 
online SEC desalting was found to be much more efficient compared to manual desalting, leading to 
nearly baseline resolution of trastuzumab glycoforms. A 6.7-fold increase in MS peak resolution was 
obtained for the fast desalting on the BEH200 4.6x30mm column vs. manual desalting, along with 20 
ppm mass accuracy. Best MS peak resolutions were obviously obtained on the longest columns 
(BEH200 4.6x300mm), with an 8-fold increase in peak resolution leading to nearly baseline resolution 
of trastuzumab glycoforms along with a subsequent improved mass accuracy (7 ppm for G1F/G0F 
glycoform of trastuzumab by SEC-native MS on the BEH200 4.6x300mm column compared to 128 
ppm by manual desalting).  
- Figure 3 -  
 
3.1.4. Hyphenation of ion mobility to online SEC-nativeMS 
We next evaluated the possibilities to perform automated native IM-MS data acquisition. Native IM-
MS provides a direct size/shape measurement for global mAbs conformation assessment [5]. A good 
agreement was found between TWCCSN2 values obtained by SEC-native IM-MS and those obtained by 
off-line injection of manually desalted mAb formats (see Supplementary Table S1) demonstrating that 
SEC-native MS configuration does not affect global conformation. These results clearly demonstrate 
the possibility to automate IM-MS data acquisition through online SEC coupling, IM-MS data 
processing appears therefore as the major bottleneck towards full automation. 
 
3.1.5. Benchmarking of the online SEC-native MS analysis of 22 mAbs and related compounds   
We finally aimed at benchmarking our online SEC-native MS workflow and analyzed a panel of 18 
therapeutic “naked” mAbs of different types (chimeric, humanized and human), isotypes (IgG1, 2 and 
4) and produced in different production systems (CHO, NSO and SP2/0) (Table 1). Based on these 
experiments, MS peak resolutions of the most intense charge state were higher than 2200 for all mAbs, 
with a distribution of values ranging from 2215 at m/z 5448.9 for panitumumab to 3542 at m/z 5347.8 
for atezolizumab. Mass accuracies were always below 75 ppm, ranging from 6.7 ppm for natalizumab 
and 73.8 ppm for pembrolizumab, which is far better than the mass accuracies reported on similar Q-
TOF instruments using the manual desalting sample preparation [11, 12]. With online SEC-native MS, 
nearly baseline resolution of mAb glycoforms was always achieved, bringing data obtained on Q-TOF 
instruments at the same level of performances, as those obtained on high resolution Orbitrap platforms 
[11, 12]. No significant differences on desalting efficiencies were observed for mAbs neither as a 
function of their hydrophobicity nor of their pI (Table 1) [34], demonstrating the versatility of the online 
SEC-native MS for fast mAb desalting. We also analyzed some other types of mAb derivatives, 
including ADCs (cysteine-, lysine- or site specific ADCs) and a bispecific mAb (blinotumumab). For 
ADCs, drug load distributions (DLDs) along with average DARs could be unambiguously determined 
(Table 1, Supplementary Figure S1) from online SEC-native MS experiments (3.9 ± 0.1 for BV, 3.4 ± 
0.1 for T-DM1 and 3.9 ± 0.1  for CBW-03-106) and were in good agreement with data resulting from 
manual sample preparation [11, 12]. Altogether, our results demonstrate that the online SEC-native MS 
analysis can be considered as a versatile and fully automated alternative for routine native MS/IM-MS 
analysis, compatible with the mass accuracy, MS peak resolution and throughput requirements of 
biopharmaceutical industries. 
- Table 1 -  
 
3.2. On-line SEC-IM-MS for forced degradation studies 
We next evaluated the possibilities to use online SEC-native IM-MS for the characterization of critical 
mAb-related HMWS impurities, such as mAb dimers, and side products derived from hinge 
fragmentation (LMWS) [35], that may cause immunogenic responses, have differences in 
pharmacokinetics or potency compared to the main product [36, 37]. As proof-of-concept, the benefits 
of online SEC-nativeMS/IM-MS workflow vs. SEC-UV or native MS used as standalone techniques for 
aggregation studies were illustrated with two representative examples: a temperature-stressed NISTmab 
(Fig. 4) and a pH-stressed trastuzumab sample (Fig. 5). 
3.2.1. Online SEC-native MS analysis of forced degraded NISTmAb for simultaneous LMWS and 
HMWS characterization   
To demonstrate the ability of our SEC-native MS methodology to simultaneously characterize HMWS 
and LMWS, we used a temperature-stressed NISTmAb sample to generate both aggregates and hinge-
related fragments [38] (see Material and Methods). Its online SEC-native MS analysis revealed four 
peaks (Fig. 4A). The most intense one (peak 2) could be attributed to the monomer (148 201 ± 2 Da), 
while peak 1 eluting in the HMWS zone, was attributed to dimeric aggregates (296 933 ± 6 Da, Fig. 
4B.). The relative amount of HMWS quantified by SEC-UV was similar in both stressed and unstressed 
samples (around 1%). Peaks 3 and 4, which elute after the main peak of the NISTmAb monomer, were 
identified as LMWS corresponding to Fc-Fab (101 074 ± 9 Da) and Fab (47 627 ± 1 Da) fragments. In 
this example, the amount of LMWS was estimated to be 4.2% from SEC-UV quantification. Comparison 
of stressed and unstressed NISTmAb samples shows that the fraction of HMWS stays unchanged upon 
stress, while an increased amount of LMWS was detected. This experiment emphasizes the ability of 
our SEC-native MS methods to simultaneously identify HMWS and LMWS under similar MS 
conditions.  
- Figure 4 -  
 
3.2.2. Benefits of online SEC-native IM-MS analysis of pH-stressed trastuzumab vs SEC-UV or 
native MS as standalone techniques 
A pH stressed trastuzumab sample to generate aggregates was produced similarly to Kukrer et al. [20]. 
We first analyzed stressed and unstressed trastuzumab samples by native MS as standalone method, 
with manual desalting. As depicted in figure 5A, very similar native mass spectra were obtained, with 
the main ion distribution being attributed to monomeric trastuzumab and the minor one to dimers. No 
higher order oligomeric states could be detected neither for stressed, or for unstressed samples. As 
monomeric and dimeric ions are expected to have very different electrospray ionization efficiencies, it 
is often tricky, if not impossible, to perform relative intra-spectrum monomer/dimer ratio estimation 
based on standalone native MS. However, as strictly identical instrumental parameters were used in both 
cases, relative inter-spectra monomer/dimer ratio could be compared for stressed and unstressed 
conditions and estimated as 95% monomeric species and 5% dimers. Native MS analysis with manual 
desalting thus allowed concluding that no significant differences exist, in terms of HMWS and LMWS, 
between stressed and unstressed trastuzumab.  
We next performed online SEC-native IM-MS analysis of both samples on the longest column (Acquity 
BEH200 4.6x300 mm, 1.7µm), to achieve the best possible chromatographic separation, with a 100 mM 
AcONH4 pH 6.8 mobile phase and the flow rate gradient previously described. Figure 5B shows the 
SEC-UV chromatogram obtained for both stressed (red trace) and unstressed (blue trace) trastuzumab. 
From the sole use of SEC-UV data, a significantly higher amount of HMWS (19.0%) was observed for 
pH stressed trastuzumab sample, which is contradictory to native MS results. However, the use of SEC-
UV as a standalone method does not afford identification of HMWS, which clearly demonstrates the 
necessity and benefits of online SEC-native MS setups.  
Online SEC-native IM-MS analyses were thus performed and revealed a main peak for unstressed 
trastuzumab, that could be attributed to monomers (148 223 Da ± 1 Da, see Supplementary Figure S2), 
along with the presence of very low amounts of HMWS (below 0.5%, as quantified by SEC-UV), which 
could be identified by native MS, as dimers (296 252 Da ± 7 Da, see Supplementary Figure S2). Of 
note, even very low quantities of HMWS were detected by native MS with a good signal-to-noise ratio 
on mass spectra while no LMWS were detected. Conversely, online SEC-native IM-MS analysis of pH 
stressed trastuzumab revealed three peaks. The most intense peak 3 could be attributed to monomeric 
trastuzumab (148 222 ± 1 Da), while peaks 1 and 2 were attributed to dimeric (296 444 ± 4 Da) and 
trimeric (444 667 ± 7 Da) aggregates, respectively (Fig. 5C). Of note, no LMWS were detected neither 
for the pH-stressed nor the unstressed trastuzumab samples. TWCCSN2 of the different species were 
estimated from IM-MS data (Fig. 5D), allowing conformational characterization of each SEC separated 
species. TWCCSN2 values for monomeric trastuzumab (79.0 ± 0.1 nm²) were in agreement with previously 
published data obtained by manual injection native IM-MS analysis [12], demonstrating that SEC does 
not affect conformation. Conformational characterization was also obtained for dimeric (TWCCSN2 = 
126.5 ± 0.1 nm²) and trimeric (TWCCSN2 = 176.7 ± 0.1 nm²) HMWS. Of note, IM-MS measured TWCCSN2 
for trastuzumab oligomers were slightly higher than those predicted from the mass (CCSdimer = 108 nm², 
CCStrimer = 142 nm²). More interestingly, the IM-MS calculated TWCCSN2 values were lower than the 
ones calculated, considering that the CCS of a dimer should be twice (and a trimer three-times) the CCS 
of the monomer (2x TWCCSN2 = 158 nm², 3x TWCCSN2 = 237 nm²), suggesting a significant 
conformational compaction upon mAb aggregation. This first example clearly highlights the benefits of 
online SEC-native MS/IM-MS compared to standalone techniques. Indeed, SEC provides HMWS 
separation which no more bias mass spectra analysis, as dimers are eluted in a different region of the 
chromatogram than the monomers. Consequently, SEC-based quantification of the relative HMWS was 
found to be more accurate than native MS-based quantitation, biased by the assumption of similar 
ionization efficiencies for species of very different masses. Conversely, mass identification of SEC-
separated species appears as a prerequisite to avoid misinterpretation due to retention time- rather than 
mass-based identifications. Finally, the combination of SEC-nativeMS/IM-MS is a win to win 
configuration as both techniques benefits from each other’s advantages along with circumventing their 
respective drawbacks. 
- Figure 5 -  
 
 
 
 
   
4. Conclusions 
We have presented here the potential of online SEC-native MS for the intact mass characterization of a 
wide range of therapeutic proteins. First, online hyphenation of SEC to native MS allows automated 
sample preparation (desalting), resulting in high-resolution intact protein mass spectra and subsequent 
accurate mass measurements (< 80 ppm). Native MS/IM-MS is now ready for high throughput routine 
intact mAbs analysis through its online hyphenation of SEC. We have next demonstrated the 
applicability of online SEC-native MS/IM-MS for forced degraded studies on several therapeutic mAbs. 
Having native MS directly coupled to SEC affords unambiguous identification of SEC separated species, 
even when poor SEC separation is achieved.  
The possibility to easily hyphenate non-denaturing SEC to non-denaturing MS constitutes a real 
technological breakthrough, allowing automation of labor extensive manual sample preparation (i.e., 
buffer exchange) which is a prerequisite to succeed in native MS analysis. For protein therapeutics 
analysis, online SEC-native MS/IM-MS not only offers the possibility to automatize native MS analysis, 
but also: i) considerably improves the quality of the MS data with increased MS peak resolutions and 
subsequently better mass accuracies; ii) reduces the analysis time per sample from few hours (depending 
on the manual desalting procedure used) to few minutes without any additional sample treatment and 
iii) allows simultaneous quantification (through SEC-UV), identification (native MS) and 
conformational characterization (IM-MS) of all SEC separated species. Altogether, we believe that with 
online SEC-native MS, the native MS technology is ready to be integrated in intact protein high 
throughput analytical workflows in biopharmaceutical companies. Online SEC-native MS/IM-MS can 
indeed provide information on multiple critical quality attributes (i.e., glycosylation profiles, drug load 
distributions and average drug-to-antibody for ADCs, aggregates and fragments, etc.) within a single 
few minutes run, for a wide variety of mAb-related compounds through accurate intact mass 
measurements without any prior sample preparation. 
Online SEC-native MS/IM-MS could also be of significant interest when SEC separation capabilities 
are exploited (e.g. for mAb aggregation studies). Indeed, the major drawback of SEC as standalone 
technique for aggregation studies is that it lacks MS- based accurate mass identification of the separated 
compounds. The direct combination of SEC to native MS is thus straightforward for unambiguous 
HMWS and LMWS peak assessment, affording simultaneous peak identification through accurate 
native MS mass measurement along with size variants quantification achieved by SEC-UV. Even if 
ammonium acetate is known to be not optimal for such applications [39], the possibility to have 
unambiguous mass-based identification online with SEC separation makes online SEC-native MS/IM-
MS appealing. By adding ion mobility, a direct conformational characterization of all SEC separated 
species is also possible within a single run. We expect that the development of new SEC column 
technologies will even contribute to increased throughput and improved chromatographic separation 
capabilities. Other perspectives of improvement rely on the development of comprehensive 2D 
workflows for the direct hyphenation of non-denaturing chromatography to native MS/IM-MS, as 
already described for online HIC hyphenation to native MS/IM-MS [40]. 
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Figure captions: 
Fig. 1. Native mass spectra of trastuzumab analyzed by online SEC-native MS with a constant flow rate 
of 0.25 ml/min (red trace) and a flow rate of 0.1 mL/min during the elution (blue trace). 
 
 
Fig. 2. Evaluation of different SEC columns for fast mAb desalting on trastuzumab (A-D). Left panels: 
SEC chromatograms obtained with corresponding flow rate gradients. Right panels: zoom on the 28+ 
charge state of trastuzumab in native MS conditions. MS peak resolution are given for m/z 5294.6. Mass 
accuracies are provided for the G1F/G0F glycoform. 
 
  
Fig. 3. Comparison of manual and SEC desalting efficiencies. Zoom on the 27+ charge state of 
trastuzumab manually desalted (red trace) and analyzed by SEC-native MS with an Acquity BEH200 
4.6x30mm (green trace) and with an Acquity BEH200 4.6x300mm (blue trace). MS peak resolutions 
were given for m/z 5490.7 while mass accuracies are provided for the G1F/G0F glycoform of 
trastuzumab.  
 
Fig. 4. Online SEC-native MS analysis of temperature-stressed NISTmAb sample. (A) Overlaid SEC 
chromatogram of stressed (red trace) and unstressed (blue trace) NISTmAb. (B) Native mass spectra of 
each individual SEC separated peak for the temperature-stressed NISTmAb sample.  
 
Fig. 5. Online SEC-native MS/IM-MS analysis of pH-stressed trastuzumab. (A) Native mass spectra of 
stressed and unstressed trastuzumab with manual desalting. (B) Overlaid SEC chromatograms of 
stressed (red trace) and unstressed (blue trace) trastuzumab. (C) Native mass spectra of each individual 
SEC separated peak for the pH stressed sample. (D) Ion mobility arrival time distributions (ATDs) of 
monomeric, dimeric and trimeric species along with their collision cross section (CCS) (28+ charge 
state for the monomer, 40+ charge state for the dimer and 52+ charge state of the trimer). Solid lines 
represent theoretical CCS calculated through the equation CCS=2.435*M2/3 for spherical proteins [41]. 
 
  
Table legend 
Table 1. Benchmarking of SEC-native MS analysis of 22 therapeutic proteins. Molecular weights are 
reported for the G1F/G0F glycoforms, MS peak resolutions were obtained from the 27+ charge state. 
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